All In Biotech

Drug Trial Radar · NCT05870670

A Research Study of a New Medicine NNC0519-0130 in Japanese and Non-Japanese Men

Investigation of Pharmacokinetics, Safety, and Tolerability of Multiple Subcutaneous Doses of NNC0519-0130 in Japanese and Non-Japanese Male Participants

Last checked: Nov 20, 2026Latest source record: Jun 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

22

Actual

Start

May 15, 2023

Primary completion

Oct 7, 2023

Study completion Oct 16, 2023

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
May 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

NNC0519-0130 is a new medicine which may possibly help participants with type 2 diabetes. This study, will look into how safe the new medicine NNC0519-0130 is, and we will measure its concentrations in the blood and look at its effects. This study will last for a maximum of 22 weeks and Japanese and Non-Japanese male participants will be included.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • NNC0519-0130Drug

    Administered subcutaneously.

  • PlaceboDrug

    Administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC0-24h,0130, SS: Area Under the NNC0519-0130 Plasma Concentration-Time Curve After the Last Dose in Each Treatment PeriodTime frame: From pre-dose until 24 hours post-dose relative to last dose in each treatment period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • SOUSEIKAI Sumida Hospital

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.